Who are Busilvex's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEFOTIAM, Monocid, Dtic-Dome, Cefradex, Busulfex, flucloxacillin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/busilvex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Busilvex — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Busilvex (Busilvex) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

phase 2 Matrix metalloproteinase-9 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Busilvex (Busilvex) — medac GmbH.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Busilvex TARGET	Busilvex	medac GmbH	phase 2		Matrix metalloproteinase-9
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
Monocid	CEFONICID		marketed	cefonicid	Matrix metalloproteinase-9	1984-01-01
Dtic-Dome	dacarbazine	Bayer	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1975-01-01
Cefradex	cefradine	Bristol-Myers Squibb	marketed	cefradine	Matrix metalloproteinase-9	1974-01-01
Busulfex	busulfan	Waylis	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1954-01-01
flucloxacillin	flucloxacillin	Karlstad University	marketed		Matrix metalloproteinase-9, Androgen receptor, Penicillin-binding protein 1A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Busilvex — Competitive Intelligence Brief. https://druglandscape.com/ci/busilvex. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing